Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapeOX + Toripalimab +/- Surufatinib in Neoadjuvant Therapy for High-risk Rectal Cancer
NCT07505472Phase 3Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of surufatinib in rectal cancer, sponsored by The First Hospital of Jilin University. Started Feb 2026; status: recruiting.
02
Drugs
surufatinib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07505472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505472.